Effectiveness Outcomes
There was no statistically significant difference between the atorvastatin 40mg and 80mg groups in the primary composite outcome of CVD-associated death, non-fatal ACS and non-fatal stroke at 1 month (0.8% vs. 1.3%, HR= 0.60, 95% CI 0.10-3.30; P=0.551). After adjusting for variables that are associated with ACS, including gender, age, geographical region of origin, smoking status, family history of CVD, hypertension, diabetes, CKD, PAD, CAD, index event of STEMI, index event of NSTEMI, index event of UA, primary PCI, number of deployed stents, type of stent, baseline LDL-C value, and concomitant medications for ACS, the primary composite outcome did not differ between the two groups (aHR= 0.59, 95% CI 0.04-8.13; P= 0.690). Similarly, within 1 year of discharge, the primary composite outcome did not significantly differ between the atorvastatin 40mg and 80mg groups (3.2% vs. 4.0%, HR= 0.58, 95% CI 0.22-1.50; P=0.243, aHR= 0.57, 95% CI 0.18-1.80; P=0.340) as shown in Table 3 .
Likewise, as shown in Table 4 , there was no difference in the secondary outcomes of all-cause mortality, cardiovascular mortality, fatal or non-fatal stroke, fatal or non-fatal ACS, coronary revascularization, stent thrombosis, and stent restenosis at 1 month and at 12 months post-discharge. Although atorvastatin 40mg and 80mg appeared similar in reducing LDL-C to less than 70 mg/dL (24% vs. 22.5%), atorvastatin 80mg compared to the 40mg significantly reduced the LDL-C by more than 50% from baseline (21.2% vs. 15.2%; P=0.022). However, we were able to obtain the LDL-C levels after discharge for around 40% of the patients in both groups.